Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

China S3 PMS: SAPIEN 3 China Post Market Registry Study

NCT: NCT05168826 · ACTIVE_NOT_RECRUITING

NCT IDNCT05168826
StatusACTIVE_NOT_RECRUITING
Start Date2022-01-24
Completion2035-12
SponsorEdwards Lifesciences (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.

Frequently Asked Questions

What is China S3 PMS: SAPIEN 3 China Post Market Registry Study?

China S3 PMS: SAPIEN 3 China Post Market Registry Study is a clinical trial registered under NCT05168826. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05168826?

The current status of NCT05168826 (China S3 PMS: SAPIEN 3 China Post Market Registry Study) is: ACTIVE_NOT_RECRUITING.

When did China S3 PMS: SAPIEN 3 China Post Market Registry Study start?

China S3 PMS: SAPIEN 3 China Post Market Registry Study started on 2022-01-24.

Related Devices

PMA P150036heart-valve, non-allograft tissueEdwards Lifesciences, LLC PMA P150048heart-valve, non-allograft tissueEdwards Lifesciences, LLC PMA P860057replacement Heart-valveEdwards Lifesciences, LLC K152980Flo Trac sensor, Volume View sensorEdwards Lifesciences, LLC K160084Swan Ganz CathetersEdwards Lifesciences, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑